VERALOX THERAPEUTICS
Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.
VERALOX THERAPEUTICS
Social Links:
Industry:
Biotechnology Medical Pharmaceutical Therapeutics
Founded:
2017-01-01
Address:
Frederick, Maryland, United States
Country:
United States
Website Url:
http://www.veralox.com
Total Employee:
1+
Status:
Active
Contact:
(301) 360-3502
Total Funding:
47.46 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Apple Mobile Web Clips Icon WordPress LetsEncrypt Amazon SSL By Default ReCAPTCHA Organization Schema
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Jounce Therapeutics
Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.
Naegis Pharmaceuticals
Naegis Pharmaceuticals is driven to discover new therapies that target underlying chronic inflammatory processes in eye diseases.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Hatteras Venture Partners
Hatteras Venture Partners investment in Venture Round - Veralox Therapeutics
JDRF T1D Fund
JDRF T1D Fund investment in Venture Round - Veralox Therapeutics
Genesys Capital
Genesys Capital investment in Venture Round - Veralox Therapeutics
Pappas Capital
Pappas Capital investment in Venture Round - Veralox Therapeutics
NYBC Ventures
NYBC Ventures investment in Venture Round - Veralox Therapeutics
Sanofi Ventures
Sanofi Ventures investment in Venture Round - Veralox Therapeutics
TEDCO
TEDCO investment in Series A - Veralox Therapeutics
University System of Maryland Momentum Fund
University System of Maryland Momentum Fund investment in Series A - Veralox Therapeutics
Hatteras Venture Partners
Hatteras Venture Partners investment in Series A - Veralox Therapeutics
Point Field Partners
Point Field Partners investment in Series A - Veralox Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-23 | Veralox Therapeutics Appoints Lisa Beck as Chief Business Officer |
Official Site Inspections
http://www.veralox.com Semrush global rank: 6.6 M Semrush visits lastest month: 1.05 K
- Host name: ec2-54-157-188-110.compute-1.amazonaws.com
- IP address: 54.157.188.110
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Veralox Therapeutics"
Meet the Team - Veralox Therapeutics
He joined Veralox in 2021 bringing expertise in chemistry, manufacturing, and controls (CMC), as well as broader pharmaceutical development experience relating CMC to non-clinical …See details»
About Veralox - Veralox Therapeutics
Vera (Latin for Truth) + 12-LOX Veralox. We are a clinical stage company with deep experience in drug discovery and development. Our Leadership Team has a proven track record with over 30 development candidates, 22 INDs and 10 …See details»
Veralox Therapeutics - Crunchbase Company Profile
Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts …See details»
Veralox Therapeutics Announces EMA Orphan Drug Designation …
Aug 14, 2024 · Veralox Therapeutics Inc. is developing first-in-class therapeutics targeting 12-lipoxygenase, pioneering a new class of therapies that treat the underlying pathologies of …See details»
Veralox Therapeutics Company Profile 2024: Valuation, …
Developer of small molecule therapeutics designed to target heparin-induced thrombocytopenia and thrombosis. The company's therapeutics focus on new treatment paradigms and improved outcomes for patients based on the …See details»
David J. Maloney - Co-Founder & Chief Scientific Officer at Veralox ...
Co-Founder & Chief Scientific Officer at Veralox Therapeutics Contact Dr. Dave Maloney is a scientifically trained leader with 10 years of experience in drug discovery and development …See details»
Veralox Therapeutics Announces FDA Orphan Drug ... - JDRF T1D …
Jan 26, 2021 · VERALOX Therapeutics Inc. (https://veralox.com/) is developing first-in-class therapeutics that target the underlying pathologies of diseases with unmet medical needs. The …See details»
USM Maryland Momentum Fund Portfolio Company Veralox …
Jun 23, 2021 · VERALOX Therapeutics Inc. (https://veralox.com/) is developing first-in-class therapeutics that target the underlying pathologies of diseases with unmet medical needs. The …See details»
Veralox Therapeutics Appoints Michael Hanna As Chief Medical …
Jun 23, 2021 · VERALOX Therapeutics Inc. (https://veralox.com/) is developing first-in-class therapeutics that target the underlying pathologies of diseases with unmet medical needs …See details»
Veralox Names Jonathan Mow as Chief Executive …
Jun 20, 2023 · Veralox Therapeutics Inc. is the clinical leader in developing first-in-class therapeutics targeting 12- lipoxygenase, pioneering a new class of therapies that treat the underlying pathologies of serious immune …See details»
Veralox Therapeutics Announces Favorable Results of Phase 1 …
Jul 7, 2022 · VERALOX Therapeutics Inc. (https://veralox.com/) is the clinical leader in developing first-in-class therapeutics targeting 12-lipoxygenase, pioneering a new class of therapies that …See details»
Veralox Names Jonathan Mow as Chief Executive Officer as the …
Jun 20, 2023 · Mr. Mow’s appointment comes as Veralox secured $24 million in funding to advance VLX-1005 through a Phase 2a proof-of-concept study evaluating its impact on …See details»
Veralox Therapeutics Announces IND Submission for VLX-1005 to …
Jan 12, 2021 · VERALOX Therapeutics Inc. (https://veralox.com/) is developing first-in-class therapeutics that target the underlying pathologies of diseases with unmet medical needs. The …See details»
Veralox Therapeutics Announces EMA Orphan Drug Designation …
Aug 22, 2024 · VLX-1005 is a novel, small molecule inhibitor of 12-lipoxygenase (12-LOX) intended for the treatment or prevention of thrombosis in adults with heparin-induced …See details»
Veralox Names Jonathan Mow as Chief Executive Officer as
Jun 20, 2023 · Veralox Therapeutics Inc. is the clinical leader in developing first-in-class therapeutics targeting 12-lipoxygenase, pioneering a new class of therapies that treat the …See details»
VLX-1005 Receives Orphan Drug Designation | ASH Clinical News ...
Jan 26, 2021 · The FDA granted orphan drug designation to VLX-1005 as thrombosis prophylaxis in patients with heparin-induced thrombocytopenia (HIT). According to its manufacturer, …See details»
Veralox Therapeutics Raises $5.4 Million in Seed Funding Co-Led …
Sep 6, 2019 · VERALOX Therapeutics Inc. (https://veralox.com/) is developing first-in-class therapeutics that target the underlying pathologies of thrombosis and type 1 diabetes. The …See details»
Veralox Therapeutics Announces Closing Of $16.6 Million Series A ...
Jun 16, 2021 · Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet …See details»
Veralox Therapeutics Announces Closing Of $16.6 Million Series A ...
FREDERICK, Md., June 16, 2021 /PRNewswire/ -- Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying …See details»
Veralox Therapeutics Announces FDA Orphan Drug Designation …
Jan 26, 2021 · VERALOX Therapeutics Inc. (https://veralox.com/) is developing first-in-class therapeutics that target the underlying pathologies of diseases with unmet medical needs. The …See details»